Clinical trial · Interventional
Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma
Dysregulation of Glutamine Utilization in the Pathogenesis of Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial studies the utilization of glutamine by the bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) compared to multiple myeloma (MM). Results from this study may identify metabolic differences between pre-malignant and malignant clonal plasma cells in MGUS and MM, respectively. It may also allow researchers better determine the transition from MGUS to MM for the development of potential early diagnostic purposes of preventative strategies.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Monoclonal Gammopathy of Undetermined Significance | Monoclonal Gammopathy of Undetermined Significance | ONTOLOGY_EXACT | 0.98 |
| Plasma Cell Myeloma | Multiple Myeloma | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 5-Carbon C 13-labeled Glutamine | Other | — | UNRESOLVED |
| Biospecimen Collection | Procedure | — | UNRESOLVED |
| Uniformly-labeled [13C]glucose | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group I (biospecimen collection)
- description
- EX-VIVO: After an overnight fast of 6 hours, patients undergo collection of bone marrow aspirate samples.
- interventionNames
- Procedure: Biospecimen Collection
- type
- EXPERIMENTAL
- label
- Group II (biospecimen collection, glutamine, glucose)
- description
- IN VIVO: After an overnight fast of 6 hours, patients receive 13-carbon labeled glutamine or 13-carbon-labeled glucose IV over 90 minutes. Patients also undergo collection of blood and bone marrow aspirate samples.
- interventionNames
- Other: 5-Carbon C 13-labeled Glutamine
- Procedure: Biospecimen Collection
- Other: Uniformly-labeled [13C]glucose
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * At least 18 years of age * International Myeloma Working Group (IMWG) criteria for the diagnosis of either MGUS or MM Exclusion Criteria: * Unable to provide consent * Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 3 * Hemoglobin \< 8 g/dL * Women who are pregnant * Prior history of adverse events with conscious sedation
References
Publications (1)
- DERIVEDGonsalves WI, Jang JS, Jessen E, Hitosugi T, Evans LA, Jevremovic D, Pettersson XM, Bush AG, Gransee J, Anderson EI, Kumar SK, Nair KS. In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. Cancer Metab. 2020 Dec 11;8(1):29. doi: 10.1186/s40170-020-00235-4. PMID 33308307